Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. - Wikidata - wikimedia - TriplyDB

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.

http://www.wikidata.org/entity/Q33844751

about

Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents Safety and efficacy of azacitidine in myelodysplastic syndromes DNA Methylation and Chromatin Remodeling: The Blueprint of Cancer Epigenetics Epigenetic regulators and their impact on therapy in acute myeloid leukemia Potential use of histone deacetylase inhibitors in cancer therapy Combating the epigenome: epigenetic drugs against non-Hodgkin's lymphoma A perspective on dietary phytochemicals and cancer chemoprevention: oxidative stress, nrf2, and epigenomics Trials with 'epigenetic' drugs: an update Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanate Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51 Clinical Toxicities of Histone Deacetylase Inhibitors.Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia.Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS).Differentiation therapy of leukemia: 3 decades of development.Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia.Emerging therapies for acute myeloid leukemia.Histone deacetylase inhibitors induce apoptosis in human eosinophils and neutrophils.What are the endpoints of therapy for acute leukemias? Old definitions and new challenges.Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells.The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers.The NF (Nuclear factor)-κB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells.Leukaemogenesis: more than mutant genes Clinical development of demethylating agents in hematology Targeting histone deacetyalses in the treatment of B- and T-cell malignancies.Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors.Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours.Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer.Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic Demethylating agents in myeloid malignancies.Myelodysplastic syndrome and histone deacetylase inhibitors: "to be or not to be acetylated"?Interpreting clinical assays for histone deacetylase inhibitors.Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.Novel agents for the treatment of childhood acute leukemia.Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents.

P2860

Q21198868-8A6816F2-696A-401B-9F3F-FC9FDD719FBB Q24596561-212D0E47-66E0-4603-AB05-4DF3A019C50E Q26749421-874FFA7F-19AF-45A1-B343-6B58F712AB45 Q26765402-4B69C3BB-EEEC-47C7-BA60-FAD4C591CE2E Q26769594-4E22AFD9-80EC-40BC-9F2B-9CE2EA106A1E Q26851166-2FBBCD67-069C-40DB-A603-EEB58735661F Q26852571-09EC2AE1-476A-43D0-8375-467AAB74B4E8 Q27000542-049DB860-7876-4054-ADDC-690259279ECC Q28082536-782B5C60-88C9-4B89-85F6-54205EF51708 Q28383320-71F5F441-83F7-41DB-B40C-F35A6350B7C1 Q28476348-027E7029-D03C-4347-9888-F194A2E2DF8C Q28533896-356CCBC0-CF45-4241-BD91-7B721DF333CC Q28535006-59D070F4-8AA0-4D38-8FAB-73513A9D682D Q31135325-20B57444-A0EA-4F3B-9344-04FF7A6D5024 Q33386193-0477DF3A-0DD8-47E8-898B-2411DB06B78C Q33395173-E85EF17A-808D-4303-840C-4D8889DF7275 Q33409795-188E361A-D3FC-4C8D-99F2-EFBC85AC0E5F Q33437309-D325285C-1F9D-41C3-BE28-BECBD3334F67 Q33576363-9A868907-8EFF-47C9-B5FC-29A5F0ECA523 Q33737214-CEAB6018-E55D-4D94-8B7C-D5BD7B8B69BB Q33775647-1039AD64-5849-4DAF-989F-B371810B83E6 Q33831971-EC79038D-2E50-436A-AE3F-CA156AD92009 Q33896749-510EB1CC-B167-4380-A8BB-AE40B5298D6B Q34014818-D63735DE-A019-475B-9E67-287FA2B4E3D6 Q34107482-9E727BBD-78FC-4BF0-84DD-CA3899500F2E Q34176804-0E9946EB-B656-4295-A6D6-ACD47ED02399 Q34275371-586A09B8-2A57-4C09-AE3E-C58877F14DC4 Q34395179-E016FE21-24D7-4D3D-9641-2EC14013F4F8 Q34414452-4B71C140-7468-4DA1-BBCF-B76C355A7129 Q34416994-E6837B28-871F-4150-A58F-49D1765C62C3 Q34621838-5398EDE6-37F0-4338-8A58-DCBEE70CBAA0 Q34808616-AAEDBD54-2CE6-4D3C-9F62-B937C356B057 Q34817365-B4F03A20-2432-4329-833F-6AE7C7FBCC87 Q34847863-A82228B5-F130-4FD4-8483-2AC1B88BBBC7 Q35001132-89106E07-798E-4923-8D30-3A247F3924FD Q35003657-4BE72662-9446-4D55-BEBC-4995FB431404 Q35022833-643C6F04-C458-47B5-9EDB-347A25F2893C Q35058556-4C083E9E-C1B1-4C56-A38C-15279C62E913 Q35192790-BA1D0ABB-B74A-4F8D-89E2-881900C6C227 Q35214924-11ECD00E-FEBE-4E7D-A141-FA5823740AF3

P2860

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.

http://www.wikidata.org/entity/Q33844751

description

2008 nî lūn-bûn

@nan

2008 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

name

Phase 1 study of the oral isot ...... nhibitor MGCD0103 in leukemia.

@ast

Phase 1 study of the oral isot ...... nhibitor MGCD0103 in leukemia.

@en

type

label

Phase 1 study of the oral isot ...... nhibitor MGCD0103 in leukemia.

@ast

Phase 1 study of the oral isot ...... nhibitor MGCD0103 in leukemia.

@en

prefLabel

Phase 1 study of the oral isot ...... nhibitor MGCD0103 in leukemia.

@ast

Phase 1 study of the oral isot ...... nhibitor MGCD0103 in leukemia.

@en

P1433

Q33844751-A53A11ED-6BA8-4970-BE1D-37714A1880D3

P1476

Q33844751-85AB25FE-8FC0-4751-A27C-2EF055F8C607

P2093

Q33844751-0B76F2FF-FA65-46E8-8E84-D9DF7C3C48E2

Q33844751-0CC4216C-0709-4F16-8EEC-96FC440BA238

Q33844751-1293EB96-743A-41ED-9934-4E7E51F5703C

Q33844751-143480F0-9D41-4CFF-9BC3-520BEECD0F34

Q33844751-3931797A-E6B7-454A-9604-48A8BCD3E9F6

Q33844751-468503AB-6118-4E5E-A577-D9580E77C586

Q33844751-4EE8996D-4831-4E25-B668-80D24B2A26A2

Q33844751-8163A31D-6578-4469-AF74-051B82469A5C

Q33844751-8F87501F-17BD-4ADD-A5AA-3FD51B7D5209

Q33844751-93F2A034-0036-4CC5-870B-BF1E85172A89

P2860

Q33844751-06B35681-3A83-448F-BEAE-1B8337DDFD83

Q33844751-102B9461-B4FE-41EB-974D-77BCCAE5FE4D

Q33844751-1706146B-AA45-4452-83A0-2EC61DC0C0D1

Q33844751-3098EDC7-C7CA-46E9-884C-25173E4FF69C

Q33844751-36C9F9B7-BFF8-4692-B037-27CED0C62B1A

Q33844751-4297AA9B-A289-4AA0-B029-7AD8EA7C0451

Q33844751-4C1B90A7-F644-47FB-B2AB-9502C7FAAB9C

Q33844751-5C21D9AC-65CB-4461-81CA-60CE6761D793

Q33844751-60A31F17-A117-4262-939E-3B34E418C7F7

Q33844751-674FADB9-3FFC-433D-BCE4-72F6BD1FF1A4

P304

Q33844751-EFA22721-9A93-497A-8E6D-5E9E7AD5DDE1

P31

Q33844751-3AE1A048-4923-4E96-B0C6-6315032C75D0

P356

Q33844751-F32AA2E5-9BE5-43B0-A33E-9C1EE7A5303F

P407

Q33844751-785C5870-5D09-4BB5-9A37-2F1EFD0B56E7

P433

Q33844751-623D642C-710F-433A-8AAD-379BFF7F5106

P478

Q33844751-6549DD87-8DF1-4A76-AB16-66A188A798AD

P50

Q33844751-6E902A34-F587-4DF0-9D5E-E3AACFD85E59

Q33844751-735CADEF-7426-4BEF-8F52-927ACA34E441

Q33844751-87836CEE-1C80-4D69-B2B3-A75F164AC4CF

Q33844751-EBD1DC69-20EA-4667-9DF6-EEC6491D1369

P577

Q33844751-86295674-8627-46E3-9526-1384D205DC63

P698

Q33844751-A2EFEDFE-D3D0-41D8-B13C-3DC61AF3A028

P921

Q33844751-35C983A7-C0A1-41F9-A14E-DDA29931D93C

P932

Q33844751-45830C60-05A6-4988-913E-C6F316DEC8B5

P356

BLOOD-2007-10-115873

P1433

P1476

Phase 1 study of the oral isot ...... nhibitor MGCD0103 in leukemia.

@en

P2093

Ann Kalita

http://www.w3.org/2001/XMLSchema#string

Caroline Rousseau

http://www.w3.org/2001/XMLSchema#string

Claire Bonfils

http://www.w3.org/2001/XMLSchema#string

Eric Laille

http://www.w3.org/2001/XMLSchema#string

Gregory Reid

http://www.w3.org/2001/XMLSchema#string

Hui Yang

http://www.w3.org/2001/XMLSchema#string

Jeffrey M Besterman

http://www.w3.org/2001/XMLSchema#string

Marja Dubay

http://www.w3.org/2001/XMLSchema#string

Mark Minden

http://www.w3.org/2001/XMLSchema#string

Robert E Martell

http://www.w3.org/2001/XMLSchema#string

P2860

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

Histone acetylation in chromatin structure and transcription

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

Anticancer activities of histone deacetylase inhibitors

The discovery of NVP-LAQ824: from concept to clinic.

Chronic oral administration of CI-994: a phase 1 study.

Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.

Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study.

Histone acetylases and deacetylases in cell proliferation.

Histone deacetylase: a target for antiproliferative and antiprotozoal agents.

P304

981-989

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2007-10-115873

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

112

http://www.w3.org/2001/XMLSchema#string

P50

Jorge Eduardo Cortes

Hagop Kantarjian

Guillermo Garcia-Manero

P577

2008-05-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18495956

http://www.w3.org/2001/XMLSchema#string

P921

P932

4081529

http://www.w3.org/2001/XMLSchema#string